Compare PGIM India Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Risk | Very High | Very High |
Rating | - | 5.0 |
Min SIP Amount | ₹1000 | ₹100 |
Expense Ratio | 2.37 | 1.86 |
NAV | ₹9.73 | ₹37.51 |
Fund Started | 19 Nov 2024 | 25 Jun 2018 |
Fund Size | ₹99.70 Cr | ₹6455.55 Cr |
Exit Load | Exit load of 0.50%, if redeemed within 90 days. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
-
5.0
Min SIP Amount
₹1000
₹100
Expense Ratio
2.37
1.86
NAV
₹9.73
₹37.51
Fund Started
19 Nov 2024
25 Jun 2018
Fund Size
₹99.70 Cr
₹6455.55 Cr
Exit Load
Exit load of 0.50%, if redeemed within 90 days.
Exit load of 1% if redeemed within 15 days.
1 Year | -1.21% | -1.54% |
3 Year | - | 25.69% |
5 Year | - | 16.06% |
1 Year
-1.21%
-1.54%
3 Year
-
25.69%
5 Year
-
16.06%
Equity | 98.07% | 97.87% |
Cash | -0.20% | 2.13% |
Equity
98.07%
97.87%
Cash
-0.20%
2.13%
Top 10 Holdings |
|
|
Top 10 Holdings
Sun Pharmaceutical Industries Ltd. | 11.72% |
Divi's Laboratories Ltd. | 9.97% |
Max Healthcare Institute Ltd. | 7.21% |
Aster DM Healthcare Ltd. | 6.23% |
Dr. Reddy's Laboratories Ltd. | 6.01% |
JB Chemicals & Pharmaceuticals Ltd. | 5.11% |
Mankind Pharma Ltd. | 4.65% |
Rubicon Research Ltd. | 4.29% |
Ajanta Pharma Ltd. | 3.92% |
Abbott India Ltd. | 3.61% |
Sun Pharmaceutical Industries Ltd. | 12.05% |
Cipla Ltd. | 7.90% |
Dr. Reddy's Laboratories Ltd. | 7.82% |
Divi's Laboratories Ltd. | 7.10% |
Mankind Pharma Ltd. | 6.44% |
Lupin Ltd. | 5.78% |
Aurobindo Pharma Ltd. | 5.19% |
Alkem Laboratories Ltd. | 3.66% |
Cohance Lifesciences Ltd. | 3.01% |
Syngene International Ltd. | 2.98% |
Name | Vivek Sharma | - |
Start Date | 11 Nov 2025 | - |
Name
Vivek Sharma
-
Start Date
11 Nov 2025
-
Description | The scheme seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 19 Nov 2024 | 25 Jun 2018 |
Description
The scheme seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
19 Nov 2024
25 Jun 2018